About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Cannabidiol (CBD) Significantly Reduces Severe Epilepsy Seizures

by Sushma Rao on May 17, 2018 at 1:07 PM
Font : A-A+

 Cannabidiol (CBD) Significantly Reduces Severe Epilepsy Seizures

Cannabidiol (CBD), a compound from the cannabis plant has been gaining much attention lately in medical research. A recent randomized, controlled trial showed that low doses of cannabidiol could significantly reduce the number of serious seizures in patients with Lennox-Gastaut syndrome - a severe form of epilepsy.

In the new study comparing two doses of CBD to a placebo, the researchers reported a 41.9 percent reduction in "drop seizures" - a type of seizure that results in severe loss of muscle control and balance - in patients taking a 20 mg/kg/d CBD regimen, a 37.2 percent reduction in those on a 10 mg/kg/d CBD regimen, and a 17.2 percent reduction in a group given a placebo.

Advertisement


The phase III trial was led by principal investigator and study first co-author Orrin Devinsky, MD, a professor of neurology, neurosurgery, and psychiatry at NYU School of Medicine and director of NYU Langone's Comprehensive Epilepsy Center, and was published in The New England Journal of Medicine.

"This new study adds rigorous evidence of cannabidiol's effectiveness in reducing seizure burden in a severe form of epilepsy and, importantly, is the first study of its kind to offer more information on proper dosing," says Dr. Devinsky. "These are real medications with real side effects, and as providers we need to know all we can about a potential treatment in order to provide safe and effective care to our patients."
Advertisement

The study included an investigational liquid, oral formulation of CBD called Epidiolex. The product is manufactured by GW Pharmaceuticals, which operates in the U.S. as Greenwich Biosciences; GW Pharmaceuticals funded the clinical trial.

Safety of Two CBD Doses Studied

Lennox-Gastaut syndrome is a rare and severe form of epilepsy characterized by frequent drop seizures and severe cognitive impairment. Six medications are approved to treat seizures in patients with the syndrome, but disabling seizures occur in most patients despite these treatments.

Researchers enrolled 225 patients (age 2 to 55) with Lennox-Gastaut syndrome across 30 international sites in a randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of two doses of CBD: Seventy-six patients received 20 mg/kg/d CBD, 73 received 10 mg/kg/d CBD, and 76 were given a placebo. All medications were divided into two doses per day for 14 weeks. The number of seizures were monitored beginning four weeks prior to the study for baseline assessment, then tracked throughout the 14-week study period and afterwards for a four-week safety check.

Side effects occurred in 94 per of patients in the 20 mg CBD group, 84 percent in the 10 mg CBD group, and 72 percent of those taking placebo. Side effects were generally reported as mild or moderate in severity and those that occurred in more than 10 percent of patients included: sleepiness, decreased appetite, diarrhea, upper respiratory infection, fever, vomiting, nasopharyngitis, and status epilepticus. Fourteen patients taking CBD experienced dose-related, elevated liver enzymes that were reversible. Seven participants from the CBD group withdrew from the trial due to side effects compared to one participant in the placebo group.

"This landmark study provides data and evidence that Epidiolex can be an effective and safe treatment for seizures seen in patients with Lennox Gastaut Syndrome, a very difficult to control epilepsy syndrome," adds study co-first author, Anup Patel, MD, chief of Neurology at Nationwide Children's Hospital.

A study led by Dr. Devinsky published in last May's New England Journal of Medicine showed a 39 percent drop in seizure frequency in patients with a different rare form of epilepsy, Dravet syndrome. Those findings represented the first large-scale, randomized clinical trial for the compound. Open label CBD studies led by Dr. Devinsky also have shown positive results for treatment-resistant epilepsies.

In April, a U.S. Food and Drug Administration advisory panel unanimously voted to recommend approval of a new drug application for Epidiolex cannabidiol oral solution, following a meeting where researchers, including Dr. Devinsky, presented their findings. The FDA will decide whether to approve the medication in late June.

"While the news gives hope for a new treatment option to the epilepsy community, more research remains imperative to better determine the effects of CBD and other similar cannabis-derived compounds on other forms of the disease and in more dosing regimens," says Dr. Devinsky.



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Black Tea Protects against Blood Pressure and Heart Diseases
Green Mediterranean Diet may Help Repair Age-Related Brain Damages
Cervical Cancer Awareness Month 2022
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Epilepsy Febrile Fits / Febrile Convulsions Neurocysticercosis Reye’s Syndrome Convulsions Electroencephalogram Aicardi-Goutieres Syndrome Cavernous Malformation Dravet Syndrome Absence Seizure 

Recommended Reading
Epilepsy
Fits or convulsions or Epilepsy is characterized by recurrent, involuntary seizures and is ......
Cannabidiol May Protect Against Long-term Psychiatric Risks
High tetrahydrocannabinol (THC) may have long-lasting behavioral effects on adolescents. A compound ...
Marijuana-Derived Cannabidiol Drug Reduces Epilepsy Seizures
Patients who were given the oral Cannabidiol (CBD) treatment Epidiolex over a 12-week treatment ......
Convulsions
Seizure or a convulsion is a result of abnormal electrical activity in the brain. If there are two ....
Absence Seizure
Absence seizure (petit mal epilepsy) involves sudden lapse in consciousness and staring blankly into...
Aicardi-Goutieres Syndrome
Aicardi-Goutieres Syndrome is observed in infants and older children. To date, defects in 6 genes ar...
Cavernous Malformation
Cavernous malformations are malformations in blood vessels that can cause neurological disorders whe...
Dravet Syndrome
The result of a rare genetic mutation, Dravet syndrome is an unusual case of epilepsy in children....
Electroencephalogram
An electroencephalogram (EEG) detects electrical activity in the brain using electrodes attached to ...
Febrile Fits / Febrile Convulsions
High fever in kids can cause convulsions and are called febrile fits that do not include the seizure...
Neurocysticercosis
Neurocysticercosis or Cysticercosis of brain is the most common cause of epilepsy and the most commo...
Reye’s Syndrome
Reye's syndrome is a medical emergency chiefly affecting children and teenagers and is marked by the...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
open close
ASK A DOCTOR ONLINE
I have read and I do accept terms of use - Telemedicine

Advantage Medindia: FREE subscription for 'Personalised Health & Wellness website with consultation' (Value Rs.300/-)